Pharmac. Ther.Vol. 51, pp. 275-289, 1991 Printed in Great Britain. All rights reserved
0163-7258/91 $0.00 + 0.50 © 1991 Pergamon Press pie
Specialist Subject Editor: M. J. BRODm
D R U G METABOLISM IN CARCINOGENESIS A N D CANCER CHEMOTHERAPY M . A. GRAHAM, R. J. RILEY a n d D . J. KERR Cancer Research Campaign Department of Medical Oncology, Alexander Stone Building, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 IBD, U.K. Almtraet---42ytotoxic drugs have become invaluable for the clinical oncologist in the treatment of neoplastic disease. Frequently, these therapeutic agents are used in combination in order to combat the heterogeneity imposed by the variable tumor cell biochemistry of the neoplastic cell population. Hence, one could argue polypharmacy has become the rule rather than the exception in cancer chemotherapy, The use of such regimens obviously increases the potential for drug
0163-7258/91 $0.00 + 0.50 © 1991 Pergamon Press pie
Specialist Subject Editor: M. J. BRODm
D R U G METABOLISM IN CARCINOGENESIS A N D CANCER CHEMOTHERAPY M . A. GRAHAM, R. J. RILEY a n d D . J. KERR Cancer Research Campaign Department of Medical Oncology, Alexander Stone Building, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 IBD, U.K. Almtraet---42ytotoxic drugs have become invaluable for the clinical oncologist in the treatment of neoplastic disease. Frequently, these therapeutic agents are used in combination in order to combat the heterogeneity imposed by the variable tumor cell biochemistry of the neoplastic cell population. Hence, one could argue polypharmacy has become the rule rather than the exception in cancer chemotherapy, The use of such regimens obviously increases the potential for drug
